Edaravone Dexborneol for Treatment of Acute Ischemic Stroke With Endovascular Therapy in Extended Time Windows

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

Also called NCT04817527

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04817527
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT04817527. Randomized; single masking; primary purpose treatment. Start 2021-10-01 (actual); primary completion 2022-12-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Edaravone Dexborneol for Treatment of Acute Ischemic Stroke With Endovascular Therapy in Extended Time Windows
Acronym
EXISTENT
Condition
Stroke, Ischemic
Intervention (Drug)
Edaravone Dexborneol
Lead sponsor
First Affiliated Hospital Xi'an Jiaotong University (class: other)

Record details

Record id
cardio:ct-nct04817527
Content hash
805b84e1b631570cbdb276224c80a938b169c5f3f55789a07fd9e6bdcb92dc46